The goal of treating peripheral artery disease (PAD) in the superficial femoral artery (SFA) is limb salvage and ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
Feature | By Karene Dumoulin, Principal Analyst, Millennium Research Group
Navigating through the world of coronary stents is about to become more complex. A plethora of new products are on the ...
July 15, 2011
June 30, 2011 — Micell Technologies Inc. announced that it has completed its review of the scheduled four-month follow ...
June 30, 2011
June 16, 2011 — Johnson & Johnson subsidiary Cordis International announced Wednesday that it will cease production of ...
June 16, 2011
June 3, 2011 – New long-term data from the DIVERGE study, presented at EuroPCR 2011, showed that the use of the Axxess ...
June 03, 2011
May 25, 2011 – Boston Scientific Corp. today announced it received approval from the U.S. Food and Drug Administration ...
May 25, 2011
May 25, 2011 – The U.S. Food and Drug Administration (FDA) cleared the Xience nano everolimus-eluting coronary stent ...
May 25, 2011
May 24, 2011 — Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices ...
May 24, 2011
May 23, 2011– A pooled analysis of the global Resolute clinical program presented today during a late-breaking clinical ...
May 23, 2011
May 20, 2011 - Boston Scientific Corporation today announced 12-month results from its PLATINUM Small Vessel study ...
May 20, 2011
May 20, 2011 – e-BioMatrix post-marketing surveillance (PMS) registry information presented at EuroPCR 2011 has ...
May 20, 2011
May 16, 2011 – In a coronary stent patent lawsuit, a jury said Cordis owes Boston Scientific approximately $19.5 million ...
May 16, 2011May 11, 2011 - Micell Technologies announced that positive preclinical data will be presented at the EuroPCR conference ...
May 11, 2011Feature | Dave Fornell
April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of ...
April 08, 2011In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in ...
April 08, 2011© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now